About US
Contact us
-
Vitamin D may stop conferring cardiovascular benefits: StudyNew research by Johns Hopkins scientists suggests that vitamin D, long known to be important for bone health and in recent years also for heart protection, may stop conferring cardiovascular benefit2012/1/5
-
Study: Drug research often suppressedA British Medical Journal study examinedpharmaceutical research. Milwaukee Journal Sentinel: Drug Research Routinely Suppressed, Study Author FindsDrug research, even from clinical trials sponsored b2012/1/5
-
Pfizer’s Prevenar 13 gets US approval for adultsBy Dr Ananya Mandal, MD Health authorities of United States have approved the expansion of Pfizer Inc's Prevnar vaccine for use in adults 50 and older to fight pneumonia, meningitis and other disea2012/1/4
-
FDA notes shortage of ADHD medicinesBy Dr Ananya Mandal, MD According to the U.S. Food and Drug Administration (FDA) drugs to treat attention deficit hyperactivity disorder (ADHD) are in such short supply that hundreds of patients co2012/1/4
-
Similar sounding drug names should come with warningsBy Dr Ananya Mandal, MD There have been mix ups and medication errors with similar sounding names of drugs - eye drops called Durezol and salicylic acid-containing wart remedy Duresal for example.2012/1/4
-
Drug shortages dominate 2011 headlinesAsk average consumers to identify the biggest trend in pharmaceuticals, and they'd likely come back with one word: Shortages. Supply problems affected everything from oncology drugs to anesthetics. Th2011/12/26
-
European crisis crimps pharma's financesWhile European leaders wrangled, wailed and gnashed their teeth about the sovereign debt crisis, drugmakers were feeling their own pain. Hospitals in Greece, Spain, Portugal and Italy stopped paying t2011/12/26
-
Drugmaker Merck to pay $24M to settle Medicaid caseThe drugmaker has agreed to settle a civil lawsuit that accused a former subsidiary of overpaying pharmacists for a widely used medication. The Associated Press/Washington Post: Drugmaker Merck Agr2011/12/23
-
AstraZeneca’s Faslodex given final snub by NICEThe UK's National Institute for Health and Clinical Excellence (NICE) has snubbed AstraZeneca breast cancer drug Faslodex in its final guidance, deeming it an inefficient use of NHS resources.NICE det2011/12/23
-
Drug makers eye small citiesCountry's health reforms open doors to foreign healthcare firms BEIJING / SHANGHAI - As reform of China's medical care system makes its way down to some of the smaller cities in China, multinatio2011/12/22